Introduction
Cancer is a generic term for a large group of diseases that can affect any part of the body and remains a leading cause of death worldwide. It is considered a public health problem according to the World Health Organization, and many efforts have been made towards its prevention and cure. Treatment usually involves a series of interventions, and approximately 90% of tumors can be treated with antiblastic drugs, 1,2 which makes chemotherapy the most used treatment. However, these drugs are non-selective and are toxic to healthy tissues, especially those of rapid cell proliferation. [2] [3] [4] [5] As a consequence, there is an urgent need for novel and effective drugs that act against cancer.
Several substances have been thoroughly studied for their biological activities and a very promising class are the neolignans, which are substances derived from the oxidative coupling of allyl and/or propenyl phenols and are normally found in plants of the Myristicacea family. [6] [7] [8] Neolignans have a wide range of biological effects such as antioxidant, [9] [10] [11] [12] [13] [14] antibacterial, [15] [16] [17] anti-inflammatory, 12, [18] [19] [20] [21] antifungal, 22, 23 anti-leishmanial, [24] [25] [26] [27] [28] anti-trypanosomastid, 27, 28 and anticancer activity, 13, 14, 29, 30 among others. [31] [32] [33] [34] Therefore, this type of natural product is of great synthetic and biological interest, especially in searching for novel anticancer agents. In this paper, we report the synthesis of new 8,4'-oxyneolignan analogues and the cell viability assays for different neoplasms, among leukemias and carcinomas.
(TLC) using aluminum plates from Merck (silica gel 60 F 254 ). Melting points (mp) were determined using a PFM II apparatus (model 382). Proton ( 1 H) and carbon ( 13 C) nuclear magnetic resonance (NMR) spectra were recorded on the following spectrometers: Bruker AC 250/P, Varian Mercury Plus 300 MHz, Bruker Avance 600 MHz or Varian Inova 500 MHz. Chemical shifts are reported in ppm (d) with values relative to TMS used as internal standard. High-resolution mass spectra (HRMS) were recorded on a VG AutoSpec High Resolution Mass Spectrometer (Micromass Company) or on a triple TOF 5600+ High Resolution Mass Spectrometer (AB Sciex) with internal calibration and direct solution (1 ppm in methanol).
General procedure for the synthesis of 8,4'-oxyneolignan analogues: β-ketoesters and β-ketoethers A solution of 1.02 equivalent of phenols (or 0.51 equivalent of cinnamic acid derivatives) and 1.80 equivalent of anhydrous K 2 CO 3 in anhydrous butanone (4.5 mL of solvent per mmol of phenol or cinnamic acid derivative) was stirred for 15 min at room temperature. After this period, a solution of 1.00 equivalent of α-bromoketone in anhydrous butanone (1.5 mL of solvent per mmol of ketone) was added dropwise and the mixture was stirred under reflux for 24 h. The solution was cooled to room temperature, filtered, and the residue washed with CHCl 3 . The solution was concentrated in vacuum (to remove butanone), diluted with H 2 O, and extracted with CHCl 3 (3×). The organic extracts were combined, washed with water, 5% NaOH solution, brine, dried over Na 2 SO 4 and then filtered and concentrated in vacuum. The reaction products were purified by crystallization or column chromatography.
2-(4-Nitro-phenoxy)-1-phenyl-ethanone (3a)
Obtained according to the general procedure from 1.50 g (10.76 mmol) of 4-nitrophenol, 2.10 g (10.55 mmol) of phenacyl bromide, 2.62 g (19.00 mmol) of K 2 CO 3 and purified by recrystallization from acetone/hexane (84% yield). The product obtained was an orange crystalline solid (mp 148-150 °C 
Obtained according to the general procedure from 0.21 g (1.28 mmol) of p-hydroxycinnamic acid, 0.50 g (2.51 mmol) of phenacyl bromide and 0.62 g (4.52 mmol) of K 2 CO 3 and purified by recrystallization from acetone (55% yield). The product obtained was a colorless crystalline solid (mp 145-147 °C 
Obtained according to the general procedure from 0.10 g (0.53 mmol) of p-hydroxycinnamic acid, 0.25 g (1.03 mmol) of 4-methoxy-8-bromopropiophenone and 0.26 g (1.85 mmol) of K 2 CO 3 and purified by recrystallization from methanol (71% yield). The product obtained was a colorless crystalline solid (mp 142-144 °C 
3-[3-(2-Oxo-2-phenyl-ethoxy)-phenyl]-acrylic acid (5a)
Obtained according to the general procedure from 0.42 g (2.56 mmol) 3-hydroxycinnamic acid, 1.00 g (5.02 mmol) of phenacyl bromide and 1.24 g (9.00 mmol) of K 2 CO 3 and purified by recrystallization from methanol (76% yield). The product obtained was a white crystalline solid (mp 139-141 °C). (E)-Methyl 3-(3-((1-oxo-1-phenylpropan-2-yl)oxy)phenyl) acrylate (8) Obtained according to the general procedure from Human myeloid leukemia (KG-1, K-562, HL-60, NB4), human burkit lymphoma (RAMOS, RAJI), human lymphoid T leukemia (JURKAT, CEM, MOLT-4), human lymphoid B leukemia (NALM-6, SUP-B15, RS4;11), human prostatic adenocarcinoma (PC3, LNCaP), human ovarian carcinoma (NCI/ADR), human malignant neoplasm cervix uteri (HeLa), human breast adenocarcinoma (MCF-7), human osteosarcoma (HOS, U-2 0S, MG-63), human glioblastomaastrocytoma, epithelial-like (U-87 MG), human glioblastoma cell lines (U-138 MG) and human non-small cell lung cancer (NCI-H1299) were cultured in RPMI medium supplemented with 10% fetal calf serum (Gibco 16000-044), 1% penicillin (10,000 IU mL -1 ) and streptomycin 10 mg mL -1 (15,070 Gibco) and exposed to concentration of drugs (10 μM) in DMSO (0.1%) and maintained at 37 °C in 95% humidified atmosphere, containing 5% CO 2 .
In vitro cell viability assay -MTT assay
All steps in this assay were automated in Liquid Handling Workstation epMotion ® 5070 (Eppendorf, Vaudaux, Schonenbuch, Switzerland). Cells were distributed in 96 wells (100 μL cells well -1 ) and incubated for 48 h, before addition of test compounds. Cells were then exposed to the compounds at a concentration of 10 μM. After 24 h of exposure at 37 °C, cell viability was determined by colorimetric MTT 35 (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) based on the metabolic ability of active cells to convert the yellow MTT reagent into a blue insoluble salt (formazan), which is spectrophotometrically measured. Then, the amount of formazan produced was dissolved in solution containing 150 μL of isopropanol and optical density was read by a spectrophotometer at 570 nm (Bio-Tek Power Wave XS). Absorbance of wells containing the compounds and those with cells in control (cells treated with vehicle, 0.1% DMSO) were compared to estimate the cell viability. The results were expressed as inhibition percentage relative to control (considered as 100%) and doxorubicin was used as a reference drug. Compound 6c was also evaluated for cytotoxicity against human leukemia cells, using the MTT method. Doxorubicin was used as positive control. All assays were performed in triplicate and mean ± standard deviation (SD) values were used to estimate cell viability.
Results and Discussion

Chemistry
In this work, 25 oxyneolignan analogues (β-ketoethers or β-ketoesters) were synthesized and the synthetic strategies for their preparation are summarized in Scheme 1. The β-ketoethers and β-ketoesters analogues  3a-3j, 4a-4c, 5a-5b, 6a-6f, 7a-7b, 8 and 9 (Table 1) were obtained following a procedure described by Barata et al. 26 Initially, the α-bromoketone intermediates 2a-2b were prepared according to a known procedure, 26 then, without any purification due to their lacrimogenic property, were reacted with an in situ generated phenoxy and/or carboxylate ion. These condensation reactions were carried out in the presence of K 2 CO 3 and butanone as solvent furnishing the products in yields ranging from 40 to 100%. The phenolic/carboxylic compounds were used in an excess of 2% instead of using excess of α-bromoketone. During isolation, the volume of solvent was reduced to 1/3 of the initial volume before work-up, since the slight solubility of the solvents in water hampers the isolation procedure.
In order to obtain compounds 7a-7b and 8, previous esterification of the cinnamic acid derivatives with Vol. 28, No. 11, 2017 methanol and sulfuric acid was mandatory to avoid the competitive nucleophilic displacement of the bromine atom by the carboxylate anions. This was confirmed in the obtention of compounds 4a-4c and 5a-5b by using 2 equivalents of 2a-2b. As far as we know, this creates a new subclass of 8,4'-oxyneolignan analogues, which we called 8,4'-oxyneolignan cinnamic analogues. Compound 9 was synthesized in a similar fashion. The 1 H NMR spectra of the products show the presence of one peak (compounds 3, 6, 7 and 8) or two peaks (compounds 4, 5 and 9) in between 5.12-6.14 ppm, assignable to the CH 2 /CH carbinolic protons. These signals confirm the formation of the C-O-C bond and, consequently, the expected products.
All synthesized substances were purified by crystallization and fully characterized by usual spectroscopic methods (melting points, HRMS, 1 H and 13 C NMR). The chemical structures are described in Table 1 .
Biology
To evaluate the antiproliferative activity, the amount of surviving cells at the dose level of 10 μM was measured after 24 h of incubation by the MTT method colorimetric assay 35 and the results were expressed as percentage of inhibition relative to control and compared with the reference drug (doxorubicin). The tests were carried out in triplicate, using doxorubicin as positive control and these data are schematically listed in Table 2 . Vol. 28, No. 11, 2017 The antiproliferative screening results show that five compounds presented a promising antiproliferative activity (≥ 50% of cell inhibition) against the leukemia cell lines. The other analogues were less active or completely inactive at the dose of 10 μM. Compounds 4a, 4b, 6d and 9 (entries 11, 12, 19 and 25, respectively) demonstrate similar inhibition of growth proliferation against HL-60, Ramos and Nalm-6 (48.6-66.7%). The same substances did not reveal a good inhibition level against K-562 cells. The best compound of the series was 6c (entry 18) inhibiting cell proliferation over 50% against four leukemia cell lines and very comparable to the positive control used in this test (entry 26). For Nalm-6 and Ramos cells, the percentage of inhibition was even superior to doxorubicin inhibition, presenting 73.2 and 84.6%, respectively.
Compounds which presented significant activity profile against leukemia cells (4a, 4b, 6c, 6d, 9 ) were selected to be evaluated for their activity on cell proliferation on other nineteen different kinds of human neoplasms, among tumors and leukemia cell lines. These tests were performed by using the MTT method, as previously mentioned. The cells used in this evaluation are listed in the Experimental section and the obtained results are shown on Tables 3-4 and Figures 1-2.
As can be seen from Table 3 and Figures 1-2 , all compounds exhibited some degree of activity against the eleven tumor cells used in this assay. β-Ketoester 6c presented a good antiproliferative activity for tumors, specially LNCaP (74.9%), HOS (68.3%) and MG-63 (70.2%), whereas compound 6d showed an inhibition rate greater than 50% only for LNCaP (50.6%), HeLa (51.4%) and HOS (65.0%) tumors. The oxyneolignan analogue 9 demonstrated a considerable reduction of cell growth on four tumor cells: LNCaP (50.0%), NCI/ADR (58.4%), U-138 MG (53.0%) and MG-63 (54.0%). 8,4'-Oxyneolignan cinnamic analogues 4a and 4b were shown to be active against most cells, exhibiting a good inhibition profile. The most active compound was 4a, showing a significant inhibition rate of cell growth against PC3 (82.9%), MG-63 (71.7%), U-87 (72.2%), U-138 MG (75.7%) and H1299 (73.4%) tumors. In these last three cell lines results, the activity of the oxyneolignan 4a was even superior to that of doxorubicin, the positive control used in this trial.
The evaluation of compounds 4a, 4b, 6c, 6d and 9 on leukemic cells are expressed in Table 4 and Figures 3-4 .
Compound 9 was most active against CEM, SUP-B15, MOLT-4 and RS4;11 cells, reducing its growth by 50.5 to 62.0%. Compound 4a presented levels of cell inhibition against KG-1, JUKART, CEM, RS4;11 around 52.4-56.8%, whereas a great selectivity and stronger antiproliferative activity were observed for compound 4b, which exhibited 92.0% of inhibition against KG-1 cells.
Compound 6c was found to be the most promising of the series, presenting antileukemic activity higher than 50% for all cell lines used in this study and superior or comparable results when compared to the reference drug. In the case of KG-1 cells, the extent of inhibition levels of products 4b and 6c were even better than doxorubicin, indicating its possible efficacy against this leukemia type.
Considering the results obtained in the antiproliferative tests (Table 4 , Figure 4) , in vitro cytotoxicity assay was used to assess the activity of the most potent compound (6c). The analogue was tested against eleven human leukemic cell lines. The assays were carried out in triplicate, and doxorubicin was used as the positive control. The biological endpoint was determined according to the concentration, 
